For investors seeking momentum, State Street SPDR S&P Biotech ETF XBI is probably on the radar. The fund just hit a 52-week high and has risen 85.43% from its 52-week low price of $66.66/share. But ...

Launched on 06/23/2005, the Invesco Biotechnology & Genome ETF (PBE) is a smart beta exchange traded fund offering broad exposure to the Health Care ETFs category of the market. What Are Smart Beta ...

The biotech sector, tracked by iShares Biotechnology ETF, rallied 40% in six months on rising M&A activity, still below four-year levels. Read why IBB ETF is a hold.

Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.

Biotech Insiders Are Spending Billions. Trump Favors Less Oversight. One Biotech ETF Could Ride the Surge. The SPDR S&P Biotech ETF is a compelling investment option.

Biotech strength is back, with IBB, PBE, FBT, CANC and HELX climbing as cheaper valuations, rate-cut hopes, FDA approvals and strong deal activity fuel biotech gains.

Biotech companies are making a solid comeback following an extended slump as investors shift their focus back to value and ...

CANC is up +48.0% year-to-date, compared with +15.7% for the S&P 500 index. Based on Bloomberg's defined universe of 47 healthcare and biotechnology ETFs, that return places CANC among the top 3 ...

Thanks to some favorable news from the Food and Drug Administration (FDA) and more mergers and acquisitions activity, biotechnology stocks and exchange traded are shaking off their previously ...

that finally saw the French pharma giant get the biotech firm for $20.1 billion. The biotech sector was active on the M&A front last year and expectations are in place for more of the same this year.